“One-Twentieth the Cost, Weeks Instead of Months… 

A Platform That Redefines Preclinical Testing”

Original HIT News interview by Yesle Shim, published on April 3, 2025

“1/20 the cost, weeks instead of months...

redefining the structure of preclinical testing”

Dr. Young Mo Kang, CEO of Preclina, emphasized, “Conventional mouse models often produce distorted or absent responses to human proteins or cells, which has historically necessitated the use of primate studies to validate the true mechanism of action of biologics.” He added, “What we offer is not merely an alternative, it represents a structural innovation that overcomes these fundamental limitations.”

Preclina’s fully humanized mouse models enable precise immune response data comparable to those obtained from non-human primates, while significantly reducing costs to less than one-twentieth and shortening study timelines from several months to just a few weeks. This is not a simple substitute, it is a transformative platform that reshapes the foundation of preclinical testing.

The Only Domestic Supply Chain in Korea

...Driven by Rigorous Optimization

The successful development of this platform was the result of years of meticulous preparation. Dr. Kang identified the localization of the supply chain as a critical milestone. At a time when most Umbilical Cord Blood-derived HSCs and Peripheral Blood Mononuclear Cells (PBMCs) were imported, Preclina established the PROBUS Network in collaboration with domestic obstetricians. After more than 18 months of preparation, the company achieved complete supply chain localization, the first in Korea and, to date, remains the only CRO with such capability.

Furthermore, Preclina has achieved a global level of engraftment and animal survival (mortality under 5%) through years of optimization across irradiation dosage, cell injection protocols, and animal housing conditions.

PreHu-P vs. PreHu-H: Purpose-Driven Model Selection

Dr. Kang noted, “We provide finely tuned platforms to align precisely with the researcher’s experimental goals.”

Global Attention for Model Expansion

Preclina has extended its humanized platform to encompass complex immune diseases, including autoimmunity, fibrosis, and allergy models. Notably, the company became the first to develop and file international patents for humanized models of ulcerative colitis (IBD) and pulmonary fibrosis (BILF).

At Bio-Europe, Preclina held in-depth discussions with companies developing multispecific antibodies, CAR-T, and TCR-T therapies, leading to several CDA agreements. At BIO International Convention 2025, the company welcomed over 140 visitors to its booth, drawing strong interest from global pharma R&D leaders who recognized the rarity and value of such advanced humanized models.

Boston Office to Serve as Strategic Hub

Preclina will open its U.S. subsidiary this June in Boston to accelerate collaboration with local partners. Dr. Kang explained, “Rather than functioning as a simple overseas branch, our Boston site will operate as a strategic hub, providing both experimental design support and direct client services.”

He concluded, “As a CRO, we do not develop therapeutics ourselves, we remain fully focused on supporting our clients' research. That commitment to trust and technical excellence is what drives our rapid global growth.”